235 related articles for article (PubMed ID: 28248857)
21. Tumor necrosis factor-α promoter -308/238 polymorphism association with less severe disease in ankylosing spondylitis is unrelated to serum TNF-α and does not predict TNF inhibitor response.
Nossent JC; Sagen-Johnsen S; Bakland G
J Rheumatol; 2014 Aug; 41(8):1675-82. PubMed ID: 25028373
[TBL] [Abstract][Full Text] [Related]
22. IgG Galactosylation status combined with MYOM2-rs2294066 precisely predicts anti-TNF response in ankylosing spondylitis.
Liu J; Zhu Q; Han J; Zhang H; Li Y; Ma Y; He D; Gu J; Zhou X; Reveille JD; Jin L; Zou H; Ren S; Wang J
Mol Med; 2019 Jun; 25(1):25. PubMed ID: 31195969
[TBL] [Abstract][Full Text] [Related]
23. Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept.
Woo JH; Lee HJ; Sung IH; Kim TH
J Rheumatol; 2007 Aug; 34(8):1753-9. PubMed ID: 17610317
[TBL] [Abstract][Full Text] [Related]
24. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.
Davis JC; Van Der Heijde D; Braun J; Dougados M; Cush J; Clegg DO; Kivitz A; Fleischmann R; Inman R; Tsuji W;
Arthritis Rheum; 2003 Nov; 48(11):3230-6. PubMed ID: 14613288
[TBL] [Abstract][Full Text] [Related]
25. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
[TBL] [Abstract][Full Text] [Related]
26. Association of GSTM1, GSTT1, GSTP1-ILE105VAL and ACE I/D polymorphisms with ankylosing spondylitis.
İnal EE; Görükmez O; Eroğlu S; Görükmez Ö; Solak Ö; Topak A; Yakut T
Rheumatol Int; 2016 Jan; 36(1):17-23. PubMed ID: 26186891
[TBL] [Abstract][Full Text] [Related]
27. Pharmacogenetic relevant polymorphisms of CYP2C9, CYP2C19, CYP2D6, and CYP3A5 in Bhutanese population.
Dorji PW; Wangchuk S; Boonprasert K; Tarasuk M; Na-Bangchang K
Drug Metab Pers Ther; 2019 Dec; 34(4):. PubMed ID: 32004143
[TBL] [Abstract][Full Text] [Related]
28. Impaired response to treatment with tumour necrosis factor α inhibitors in smokers with axial spondyloarthritis.
Ciurea A; Scherer A; Weber U; Exer P; Bernhard J; Tamborrini G; Riek M; Müller RB; Weiss B; Nissen MJ; Kissling R; Michel BA; Finckh A;
Ann Rheum Dis; 2016 Mar; 75(3):532-9. PubMed ID: 25667205
[TBL] [Abstract][Full Text] [Related]
29. The association of NLRP3 and TNFRSF1A polymorphisms with risk of ankylosing spondylitis and treatment efficacy of etanercept.
Zhao S; Chen H; Wu G; Zhao C
J Clin Lab Anal; 2017 Nov; 31(6):. PubMed ID: 28116820
[TBL] [Abstract][Full Text] [Related]
30. The relationship between C-reactive protein rs3091244 polymorphism and ankylosing spondylitis.
Akbal A; Reşorlu H; Gökmen F; Savaş Y; Zateri Ç; Sargin B; Bozkurt E; Sılan F; Özdemir Ö
Int J Rheum Dis; 2016 Jan; 19(1):43-8. PubMed ID: 26480896
[TBL] [Abstract][Full Text] [Related]
31. Disparate effects of anti-TNF-α therapies on measures of disease activity and mediators of endothelial damage in ankylosing spondylitis.
Korkosz M; Gąsowski J; Surdacki A; Leszczyński P; Pawlak-Buś K; Jeka S; Siedlar M; Grodzicki T
Pharmacol Rep; 2013; 65(4):891-7. PubMed ID: 24145083
[TBL] [Abstract][Full Text] [Related]
32. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.
Brandt J; Khariouzov A; Listing J; Haibel H; Sörensen H; Grassnickel L; Rudwaleit M; Sieper J; Braun J
Arthritis Rheum; 2003 Jun; 48(6):1667-75. PubMed ID: 12794835
[TBL] [Abstract][Full Text] [Related]
33. Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs.
Perrotta FM; Addimanda O; Ramonda R; D'Angelo S; Lubrano E; Marchesoni A; Olivieri I; Punzi L; Salvarani C; Spadaro A
Reumatismo; 2014 Nov; 66(3):208-14. PubMed ID: 25376955
[TBL] [Abstract][Full Text] [Related]
34. The use of low-dose etanercept as an alternative therapy for treatment of ankylosing spondylitis: a case series.
Moghimi J; Sheikhvatan M; Semnani V
Rheumatol Int; 2012 Aug; 32(8):2271-4. PubMed ID: 21553278
[TBL] [Abstract][Full Text] [Related]
35. Anti-TNF-alpha therapy for ankylosing spondylitis.
Son JH; Cha SW
Clin Orthop Surg; 2010 Mar; 2(1):28-33. PubMed ID: 20190998
[TBL] [Abstract][Full Text] [Related]
36. Assessment of serum asymmetric dimethylarginine levels and left ventricular diastolic function in patients with ankylosing spondylitis.
Inci U; Yildiz A; Batmaz I; Tekbas E
Int J Rheum Dis; 2017 Feb; 20(2):238-244. PubMed ID: 26012572
[TBL] [Abstract][Full Text] [Related]
37. Fat Mass Lowers the Response to Tumor Necrosis Factor-α Blockers in Patients with Ankylosing Spondylitis.
Ibáñez Vodnizza SE; Nurmohamed MT; Visman IM; van Denderen JC; Lems WF; Jaime F; van der Horst-Bruinsma IE
J Rheumatol; 2017 Sep; 44(9):1355-1361. PubMed ID: 28711878
[TBL] [Abstract][Full Text] [Related]
38. [Clinical significance of high sensitivity C-reactive protein for evaluating the efficacy of etanercept in active ankylosing spondylitis].
Zhang J; Huang F; Zhang J; Deng X; Zhang Y
Zhonghua Yi Xue Za Zhi; 2014 Jan; 94(3):204-7. PubMed ID: 24731464
[TBL] [Abstract][Full Text] [Related]
39. Kunxian capsules in the treatment of patients with ankylosing spondylitis: a randomized placebo-controlled clinical trial.
Li Q; Li L; Bi L; Xiao C; Lin Z; Cao S; Liao Z; Gu J
Trials; 2016 Jul; 17(1):337. PubMed ID: 27449221
[TBL] [Abstract][Full Text] [Related]
40. Semaphorin 3A in Ankylosing Spondylitis.
Liao HT; Lin YF; Chou CT; Tsai CY
J Microbiol Immunol Infect; 2019 Feb; 52(1):151-157. PubMed ID: 28736223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
